Overview

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Status:
Active, not recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.
Takeda

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone acetate
Lenalidomide
Pomalidomide